Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1

Vaccine

Volumn 25, Issue 6, 2007, Pages 1132-1141

  Wang, Zhongde ^a   Rosa, Corinna La ^a   Li, Zhongqi ^a   Ly, Heang ^a   Krishnan, Aparna ^a   Martinez, Joy ^a   Britt, William J ^b   Diamond, Don J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Cytomegalovirus; IE1; pp65; Vaccine; Vaccinia

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; IMMEDIATE EARLY PROTEIN IE1; MODIFIED VACCINIA ANKARA VIRUS VECTOR; VIRUS ANTIGEN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL GENE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; EMBRYO; EXON; GENE CONSTRUCT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOGENICITY; INFECTION PREVENTION; LYMPHOCYTE ACTIVATION; MARKER GENE; MEMORY T LYMPHOCYTE; MODIFIED VACCINIA ANKARA; MOUSE; NONHUMAN; ORGAN TRANSPLANTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; POXVIRUS; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRUS RECOMBINANT;

ANIMALS; CHICK EMBRYO; GENETIC VECTORS; HUMANS; IMMEDIATE-EARLY PROTEINS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, TRANSGENIC; PHOSPHOPROTEINS; PLASMIDS; T-LYMPHOCYTES; VACCINES, DNA; VACCINIA; VIRAL MATRIX PROTEINS; VIRAL PROTEINS;

EID: 33845563315     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.09.067     Document Type: Article

References (69)

1. Mayr A. Historical review of smallpox, the eradication of smallpox and the attenuated smallpox MVA vaccine. Berl Munch Tierarztl Wochenschr 112 9 (1999) 322-328
2. Sutter G., and Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 89 22 (1992) 10847-10851
3. Sutter G., Wyatt L.S., Foley P.L., Bennink J.R., and Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12 11 (1994) 1032-1040
4. Taylor G.S., Haigh T.A., Gudgeon N.H., Phelps R.J., Lee S.P., Steven N.M., et al. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma. J Virol 78 2 (2004) 768-778
5. Harrer E., Bauerle M., Ferstl B., Chaplin P., Petzold B., Mateo L., et al. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir Ther 10 2 (2005) 285-300
6. Cebere I., Dorrell L., McShane H., Simmons A., McCormack S., Schmidt C., et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24 4 (2006) 417-425
7. Corona Gutierrez C.M., Tinoco A., Navarro T., Contreras M.L., Cortes R.R., Calzado P., et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 15 5 (2004) 421-431
8. Bejon P., Peshu N., Gilbert S.C., Lowe B.S., Molyneux C.S., Forsdyke J., et al. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya. Clin Infect Dis 42 8 (2006) 1102-1110
9. Webster D.P., Dunachie S., McConkey S., Poulton I., Moore A.C., Walther M., et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 24 15 (2006) 3026-3034
10. Dunachie S.J., Walther M., Vuola J.M., Webster D.P., Keating S.M., Berthoud T., et al. A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS, S/AS02A and MVA-CS. Vaccine 24 15 (2006) 2850-2859
11. Meyer R.G., Britten C.M., Siepmann U., Petzold B., Sagban T.A., Lehr H.A., et al. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol Immunother 54 5 (2005) 453-467
12. Di Nicola M., Carlo-Stella C., Mortarini R., Baldassari P., Guidetti A., Gallino G.F., et al. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma. Clin Cancer Res 10 16 (2004) 5381-5390
13. Dorrell L., Yang H., Ondondo B., Dong T., di Gleria K., Suttill A., et al. Expansion and diversification of virus-specific t cells following immunization of human immunodeficiency virus Type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. J Virol 80 10 (2006) 4705-4716
14. Rauser G., Einsele H., Sinzger C., Wernet D., Kuntz G., Assenmacher M., et al. Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood 103 9 (2004) 3565-3572
15. Einsele H., Roosnek E., Rufer N., Sinzger C., Riegler S., Loffler J., et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99 11 (2002) 3916-3922
16. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333 16 (1995) 1038-1044
17. Sylwester A.W., Mitchell B.L., Edgar J.B., Taormina C., Pelte C., Ruchti F., et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 202 5 (2005) 673-685
18. Elkington R., Walker S., Crough T., Menzies M., Tellam J., Bharadwaj M., et al. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 77 9 (2003) 5226-5240
19. Riddell S.R., Reusser P., and Greenberg P.D. Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients. Rev Infect Dis 13 Suppl. 11 (1991) S966-S973
20. Wills M.R., Carmichael A.J., Mynard K., Jin X., Weekes M.P., Plachter B., et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70 11 (1996) 7569-7579
21. Cobbold M., Khan N., Pourgheysari B., Tauro S., McDonald D., Osman H., et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 202 3 (2005) 379-386
22. Peggs K.S., Verfuerth S., Pizzey A., Khan N., Guiver M., Moss P.A., et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362 9393 (2003) 1375-1377
23. Cwynarski K., Ainsworth J., Cobbold M., Wanger S., Mahendra P., Apperley J., et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 97 5 (2001) 1232-1240
24. Bunde T., Kirchner A., Hoffmeister B., Habedank D., Hetzer R., Cherepnev G., et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med (2005)
25. Gyulai Z., Endresz V., Burian K., Pincus S., Toldy J., Cox W.I., et al. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J Infect Dis 181 5 (2000) 1537-1546
26. Wang Z., La Rosa C., Mekhoubad S., Lacey S.F., Villacres M.C., Markel S., et al. Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. Blood 104 3 (2004) 847-856
27. Pascolo S., Bervas N., Ure J.M., Smith A.G., Lemonnier F.A., and Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2. 1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185 12 (1997) 2043-2051
28. Wang Z., La Rosa C., Maas R., Ly H., Brewer J., Mekhoubad S., et al. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J Virol 78 8 (2004) 3965-3976
29. Britt W.J., and Auger D. Identification of a 65,000 dalton virion envelope protein of human cytomegalovirus. Virus Res 4 1 (1985) 31-36
30. Plachter B., Britt W., Vornhagen R., Stamminger T., and Jahn G. Analysis of proteins encoded by IE regions 1 and 2 of human cytomegalovirus using monoclonal antibodies generated against recombinant antigens. Virology 193 2 (1993) 642-652
31. Moss B., and Earl P.L. Expression of proteins in mammalian cells using vaccinia virus vectors. Current protocols in molecular biology (1998), John Wiley & Sons, Inc., New York, NY p. 16.15.11-16.21.19
32. La Rosa C., Wang Z., Lacey S.F., Lalimarmo M.M., Krishnan A., Longmate J., et al. In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara. Exp Hematol 34 4 (2006) 497-507
33. La Rosa C., Krishnan R., Markel S., Schneck J.P., Houghten R., Pinilla C., et al. Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries. Blood 97 6 (2001) 1776-1786
34. Lacey S.F., Villacres M.C., La Rosa C., Wang Z., Longmate J., Martinez J., et al. Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum Immunol 64 4 (2003) 440-452
35. Ourmanov I., Brown C.R., Moss B., Carroll M., Wyatt L., Pletneva L., et al. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J Virol 74 6 (2000) 2740-2751
36. Drexler I., Staib C., and Sutter G. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?. Curr Opin Biotechnol 15 6 (2004) 506-512
37. Carroll M.W., and Moss B. E. coli beta-glucuronidase (gus) as a marker for recombinant vaccinia viruses. Biotechniques 19 3 (1995) 352-354 356
38. Daftarian P., Ali S., Sharan R., Lacey S.F., La rosa C., Longmate J., et al. Immunization with Th-CTL fusion peptide and cytosine-phosphate-guanine DNA in transgenic HLA-A2 mice induces recognition of HIV-infected T cells and clears vaccinia virus challenge. J Immunol 171 8 (2003) 4028-4039
39. Riddell S.R., Watanabe K.S., Goodrich J.M., Li C.R., Agha M.E., and Greenberg P.D. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257 5067 (1992) 238-241
40. Staib C., Drexler I., and Sutter G. Construction and isolation of recombinant MVA. Methods Mol Biol 269 (2004) 77-100
41. Meyer H., Sutter G., and Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72 Pt 5 (1991) 1031-1038
42. Sutter G., and Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 3 3 (2003) 263-271
43. Earl P.L., Americo J.L., Wyatt L.S., Eller L.A., Whitbeck J.C., Cohen G.H., et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428 6979 (2004) 182-185
44. Falkner F.G., and Moss B. Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J Virol 62 6 (1988) 1849-1854
45. Staib C., Drexler I., Ohlmann M., Wintersperger S., Erfle V., and Sutter G. Transient host range selection for genetic engineering of modified vaccinia virus Ankara. Biotechniques 28 6 (2000) 1137-1142 1144-1136, 1148
46. Brubaker J.O., Thompson C.M., Morrison L.A., Knipe D.M., Siber G.R., and Finberg R.W. Th1-associated immune responses to beta-galactosidase expressed by a replication-defective herpes simplex virus. J Immunol 157 4 (1996) 1598-1604
47. Marktel S., Magnani Z., Ciceri F., Cazzaniga S., Riddell S.R., Traversari C., et al. Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood 101 4 (2003) 1290-1298
48. Bonini C., Grez M., Traversari C., Ciceri F., Marktel S., Ferrari G., et al. Safety of retroviral gene marking with a truncated NGF receptor. Nat Med 9 4 (2003) 367-369
49. Scheiflinger F., Dorner F., and Falkner F.G. Transient marker stabilisation: a general procedure to construct marker-free recombinant vaccinia virus. Arch Virol 143 3 (1998) 467-474
50. Hill A.V. Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat Rev Immunol 6 1 (2006) 21-32
51. Morse M.A., Clay T.M., Hobeika A.C., Osada T., Khan S., Chui S., et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res 11 8 (2005) 3017-3024
52. Goonetilleke N., Moore S., Dally L., Winstone N., Cebere I., Mahmoud A., et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 gag coupled to CD8+ T-Cell Epitopes. J Virol 80 10 (2006) 4717-4728
53. Stittelaar K.J., Kuiken T., de Swart R.L., van Amerongen G., Vos H.W., Niesters H.G., et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19 27 (2001) 3700-3709
54. Cosma A., Nagaraj R., Buhler S., Hinkula J., Busch D.H., Sutter G., et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22 1 (2003) 21-29
55. Hanke T., McMichael A.J., Dennis M.J., Sharpe S.A., Powell L.A., McLoughlin L., et al. Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. Vaccine 23 12 (2005) 1507-1514
56. Wang Z., La Rosa C., Lacey S.F., Mass R., Mekhoubad S., Britt W.J., et al. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection. J Clin Virol 35 3 (2006) 324-331
57. Johnson P.R., Schnepp B.C., Connell M.J., Rohne D., Robinson S., Krivulka G.R., et al. Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol 79 2 (2005) 955-965
58. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 6869 (2002) 331-335
59. Xiang Z., Gao G., Reyes-Sandoval A., Cohen C.J., Li Y., Bergelson J.M., et al. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 76 6 (2002) 2667-2675
60. Shiver J.W., and Emini E.A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 55 (2004) 355-372
61. Publicover J., Ramsburg E., and Rose J.K. Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses. J Virol 78 17 (2004) 9317-9324
62. Strauss J.H., and Strauss E.G. The alphaviruses: gene expression, replication, and evolution. Microbiol Rev 58 3 (1994) 491-562
63. Schlesinger S., and Dubensky T.W. Alphavirus vectors for gene expression and vaccines. Curr Opin Biotechnol 10 5 (1999) 434-439
64. Endresz V., Burian K., Berencsi K., Gyulai Z., Kari L., Horton H., et al. Optimization of DNA immunization against human cytomegalovirus. Vaccine 19 28-29 (2001) 3972-3980
65. Shimamura M., Mach M., and Britt W.J. Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response. J Virol 80 9 (2006) 4591-4600
66. Mach M., Kropff B., Dal Monte P., and Britt W. Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73). J Virol 74 24 (2000) 11881-11892
67. Rasmussen L., Geissler A., Cowan C., Chase A., and Winters M. The genes encoding the gCIII complex of human cytomegalovirus exist in highly diverse combinations in clinical isolates. J Virol 76 21 (2002) 10841-10848
68. Schleiss M.R., Stroup G., Pogorzelski K., and McGregor A. Protection against congenital cytomegalovirus (CMV) disease, conferred by a replication-disabled, bacterial artificial chromosome (BAC)-based DNA vaccine. Vaccine (2006)
69. Barry P.A., Lockridge K.M., Salamat S., Tinling S.P., Yue Y., Zhou S.S., et al. Nonhuman primate models of intrauterine cytomegalovirus infection. Ilar J 47 1 (2006) 49-64